NASDAQ : ADRX
ADARx Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.90B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
ADARx Pharmaceuticals, Inc. (ADRX) reported revenue of 6.13M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 6.13M | 3.45M | |
| Cost of Revenue | 89.87M | 71.51M | 43.36M |
| Gross Profit | -83.74M | -68.06M | -43.36M |
| Selling, General & Admin | 22.56M | 20.30M | 14.88M |
| Operating Expenses | 22.56M | 20.30M | 14.88M |
| Operating Income | -106.30M | -88.36M | -58.23M |
| Interest & Investment Income | 16.66M | 13.64M | 11.39M |
| Other Non Operating Income (Expenses) | 1.78M | 1.64M | 478.00K |
| Pretax Income | -87.87M | -73.09M | -46.36M |
| Net Income | -87.87M | -73.09M | -46.36M |
| Net Income to Common | -87.87M | -73.09M | -46.36M |
| Shares Outstanding (Basic) | 11.35M | 11.36M | 11.00M |
| Shares Outstanding (Diluted) | 11.35M | 11.36M | 11.00M |
| EPS (Basic) | -7.74 | -6.43 | -4.22 |
| EPS (Diluted) | -7.74 | -6.43 | -4.22 |
| Free Cash Flow | -90.21M | 259.35M | -49.02M |
| Free Cash Flow Per Share | -7.95 | 22.82 | -4.46 |
| Operating Margin | -1,734.98% | -2,562.05% | |
| Profit Margin | -1,434.14% | -2,119.11% | |
| Free Cash Flow Margin | -1,472.37% | 7,519.66% | |
| EBITDA | -105.12M | -87.36M | -57.50M |
| D&A For EBITDA | 1.18M | 1.00M | 730.00K |
| EBIT | -106.30M | -88.36M | -58.23M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 58.48M | 66.52M | 14.03M |
| Short-Term Investments | 368.77M | 413.48M | 205.44M |
| Cash & Short-Term Investments | 427.25M | 480.00M | 219.48M |
| Prepaid Expenses | 14.29M | 13.38M | 6.19M |
| Total Current Assets | 441.54M | 493.38M | 225.67M |
| Property, Plant & Equipment | 10.98M | 12.07M | 7.13M |
| Other Long-Term Assets | 3.81M | 2.21M | 660.00K |
| Total Assets | 456.33M | 507.65M | 233.45M |
| Accounts Payable | 4.86M | 5.84M | 1.35M |
| Accrued Expenses | 8.53M | 6.37M | 6.80M |
| Current Portion of Leases | 1.71M | 1.71M | 794.00K |
| Current Unearned Revenue | 18.91M | 16.56M | |
| Total Current Liabilities | 34.01M | 30.48M | 8.94M |
| Long-Term Leases | 5.19M | 6.03M | 3.54M |
| Long-Term Unearned Revenue | 309.76M | 314.99M | |
| Other Long-Term Liabilities | 805.00K | 781.00K | 505.00K |
| Total Liabilities | 349.76M | 352.29M | 12.98M |
| Additional Paid-In Capital | 18.86M | 16.49M | 10.13M |
| Retained Earnings | -269.12M | -220.70M | -147.61M |
| Comprehensive Income & Other | -783.00K | 1.96M | 335.00K |
| Total Common Equity | -251.05M | -202.25M | -137.15M |
| Shareholders' Equity | 106.57M | 155.37M | 220.48M |
| Total Liabilities & Equity | 456.33M | 507.65M | 233.45M |
| Total Debt | 6.90M | 7.74M | 4.33M |
| Net Cash (Debt) | 420.35M | 472.25M | 215.15M |
| Net Cash Per Share | 37.03 | 41.56 | 19.57 |
| Filing Date Shares Outstanding | 106.58M | 11.32M | 11.00M |
| Total Common Shares Outstanding | 11.33M | 11.32M | 11.00M |
| Working Capital | 407.53M | 462.89M | 216.73M |
| Book Value Per Share | -22.16 | -17.87 | -12.47 |
| Tangible Book Value | -251.05M | -202.25M | -137.15M |
| Tangible Book Value Per Share | -22.16 | -17.87 | -12.47 |
| Machinery | 8.25M | 7.89M | 5.03M |
| Construction In Progress | 15.00K | 28.00K | 286.00K |
| Leasehold Improvements | 358.00K | 358.00K | 189.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -87.87M | -73.09M | -46.36M |
| Depreciation & Amortization | 2.64M | 2.33M | 1.50M |
| Loss (Gain) From Sale of Investments | -1.38M | -2.89M | -7.09M |
| Stock-Based Compensation | 5.59M | 6.13M | 3.95M |
| Change in Accounts Payable | -813.00K | 4.47M | -223.00K |
| Change in Unearned Revenue | -6.13M | 331.55M | |
| Change in Other Net Operating Assets | -372.00K | -6.21M | -341.00K |
| Operating Cash Flow | -88.32M | 262.29M | -48.56M |
| Capital Expenditures | -1.89M | -2.94M | -455.00K |
| Investment in Securities | 82.91M | -206.99M | 39.97M |
| Investing Cash Flow | 81.02M | -209.93M | 39.51M |
| Issuance of Common Stock | 22.00K | 97.00K | 225.00K |
| Financing Cash Flow | 22.00K | 97.00K | 225.00K |
| Foreign Exchange Rate Adjustments | 119.00K | 23.00K | 6.00K |
| Net Cash Flow | -7.16M | 52.48M | -8.82M |
| Free Cash Flow | -90.21M | 259.35M | -49.02M |
| Free Cash Flow Margin | -1,472.37% | 7,519.66% | |
| Free Cash Flow Per Share | -7.95 | 22.82 | -4.46 |
| Levered Free Cash Flow | -36.27M | ||
| Unlevered Free Cash Flow | -36.27M | ||
| Change in Working Capital | -7.31M | 329.81M | -564.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.90B | ||
| Enterprise Value | 1.48B | ||
| Debt / Equity Ratio | 0.07 | 0.05 | 0.02 |
| Debt / FCF Ratio | 0.03 | ||
| Net Debt / Equity Ratio | -3.94 | -3.04 | -0.98 |
| Net Debt / EBITDA Ratio | 4.00 | 5.41 | 3.74 |
| Net Debt / FCF Ratio | 4.66 | -1.82 | 4.39 |
| Asset Turnover | 0.01 | ||
| Quick Ratio | 12.56 | 15.74 | 24.56 |
| Current Ratio | 12.98 | 16.18 | 25.25 |
| Return on Equity (ROE) | -38.89% | ||
| Return on Assets (ROA) | -14.90% | ||
| Return on Capital Employed (ROCE) | -25.20% | -18.50% | -25.90% |
| Buyback Yield / Dilution | -3.34% |